Want to see IN:GUJTHEM full AI Analyst Report?
GUJTHEM Stock Chart & Stats
₹432.00
--
Market closed
₹432.00
--
Day’s Range― - ―
52-Week Range₹225.75 - ₹479.45
Previous CloseN/A
VolumeN/A
Average Volume (3M)8.65K
Market Cap
₹39.57B
Enterprise Value₹42.95B
Total Cash (Recent Filing)₹103.83M
Total Debt (Recent Filing)₹714.92M
Price to Earnings (P/E)82.1
Beta1.98
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.19%
Share Statistics
EPS (TTM)2.41
Shares Outstanding108,965,260
10 Day Avg. Volume8,769
30 Day Avg. Volume8,646
Financial Highlights & Ratios
PEG Ratio-11.90
Price to Book (P/B)8.62
Price to Sales (P/S)14.96
P/FCF Ratio-19.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)6.9
Revenue Forecast (FY)₹1.88B
Bulls Say, Bears Say
Bulls Say
Strong Operating ProfitabilitySustained high EBIT and net margins indicate durable operating leverage and pricing power in API manufacturing. Even as volumes fluctuate, elevated margins support cash earnings ability and cushion the business versus lower-margin peers, underpinning long-term earnings stability and reinvestment capacity.
Rapid Revenue ExpansionA >100% revenue increase signals successful scaling of sales and market penetration in the API/intermediates segment. Durable higher volumes can enhance fixed-cost absorption, broaden customer footprint and create a basis for sustainable earnings growth if product quality and customer relationships persist.
Equity Cushion And Historical ROEA sizable equity base plus historically strong ROE demonstrates prior efficient capital use and provides a buffer against shocks. This structural capital strength supports investment, helps absorb losses, and reduces likelihood of immediate solvency stress even as the company manages higher leverage.
Bears Say
Rising LeverageA rapid increase in debt materially raises financial risk, interest burden and reduces strategic flexibility. Over a multi-month horizon, higher leverage constrains the ability to fund capex or working capital organically and increases sensitivity to margin or demand shocks, elevating refinancing and covenant risk.
Deteriorating Cash GenerationMaterial fall in operating cash conversion and sharply negative free cash flow imply cash burn from investment or working capital. Persistent negative FCF typically necessitates external financing, which can increase cost of capital and constrain growth or dividend policy over the medium term if not reversed.
Sharp Gross Margin DeclineA large, sustained drop in gross margin suggests structural cost pressure, adverse mix or pricing tolerance issues. If persistent, this erodes earnings quality and the company’s ability to translate top-line growth into durable profit gains, increasing vulnerability to industry cycle swings.
Gujarat Themis Biosyn Ltd News
GUJTHEM FAQ
What was Gujarat Themis Biosyn Ltd’s price range in the past 12 months?
Gujarat Themis Biosyn Ltd lowest stock price was ₹225.75 and its highest was ₹479.45 in the past 12 months.
What is Gujarat Themis Biosyn Ltd’s market cap?
Gujarat Themis Biosyn Ltd’s market cap is ₹39.57B.
When is Gujarat Themis Biosyn Ltd’s upcoming earnings report date?
Gujarat Themis Biosyn Ltd’s upcoming earnings report date is Aug 06, 2026 which is in 14 days.
How were Gujarat Themis Biosyn Ltd’s earnings last quarter?
Gujarat Themis Biosyn Ltd released its earnings results on May 25, 2026. The company reported ₹1 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.
Is Gujarat Themis Biosyn Ltd overvalued?
According to Wall Street analysts Gujarat Themis Biosyn Ltd’s price is currently Overvalued.
Does Gujarat Themis Biosyn Ltd pay dividends?
Gujarat Themis Biosyn Ltd pays a Notavailable dividend of ₹0.67 which represents an annual dividend yield of 0.19%. See more information on Gujarat Themis Biosyn Ltd dividends here
What is Gujarat Themis Biosyn Ltd’s EPS estimate?
Gujarat Themis Biosyn Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gujarat Themis Biosyn Ltd have?
Gujarat Themis Biosyn Ltd has 108,965,260 shares outstanding.
What happened to Gujarat Themis Biosyn Ltd’s price movement after its last earnings report?
Gujarat Themis Biosyn Ltd reported an EPS of ₹1 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.988%.
Which hedge fund is a major shareholder of Gujarat Themis Biosyn Ltd?
Currently, no hedge funds are holding shares in IN:GUJTHEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gujarat Themis Biosyn Ltd
Gujarat Themis Biosyn Ltd. is an Indian company primarily involved in the creation of pharmaceuticals and medicinal chemicals. The firm also supplies bulk drugs via a job work model within India. Its product offerings include important compounds such as Rifamycin-S, an intermediate used in treatments for tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease. Another key product, Rifamycin-O, addresses ailments like traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy. Furthermore, they produce Lovastatin. Established in 1981, the company's operations are based out of Mumbai, India.
Technical Analysis
Dishman Carbogen Amcis Ltd.
―
Gufic Biosciences Limited
―
Orchid Pharma Limited
―
RPG Life Sciences Limited
―
Zota Health Care Ltd.
―